Clinical Trial

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial studies how well methylphenidate and physical activity works in reducing cancer-related fatigue in patients who are receiving anti-PD1 immunotherapy for cancer that has spread to other places in the body. Central nervous systems stimulants, such as methylphenidate, may help to improve cognitive function. Physical activity uses techniques, such as aerobic and resistance exercises, which may help to improve quality of life. Giving methylphenidate and physical activity may help in reducing cancer-related fatigue in patients with metastatic cancer who receive anti-PD1 immunotherapy.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2018-05-14; most recent amendment 2026-04-10.
Status change: Recruiting → Active, Not Recruiting 2021-11-09
Status change: Not Yet Recruiting → Recruiting 2018-08-02
Trial Details
NCT Number NCT03525873
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Enrollment 212 participants
Start Date 2018-08-02
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15